Praxis Precision Medicines
PRAX369.16515.64% ( +49.935 )
Praxis Precision Medicines (PRAX)
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders...
- Open
- 350.470
- High
- 382.540
- Low
- 343.730
- Prev. Close
- 319.230
- Volume
- 941.28K
- Turnover
- 346.82M
- Avg Price
- 368.461
- Bid/Ask Ratio
- --
- Amplitude
- 12.16%
- 52wk High
- 382.540
- Volume Ratio
- 5.39
- Turnover Ratio
- 3.92%
Praxis Precision Medicines Analyst Rating
View MoreForecast & Rating
Jul 29, 2026Price forecast
$610.0565.25%
Forecast & RatingStrong buy
19analysts
- Strong buy73.68%
- Buy15.79%
- Hold5.26%
- Sell5.26%
- Strong sell0.00%
News
- Quartr · 2 hours ago
PRAX: Two late-stage therapies near FDA approval, with launches and strong financials on track
- TradingKey · 4 hours ago
Praxis Q2 2026 results: $1.4 billion liquidity supports runway into 2028
- PUBT · 5 hours ago
Praxis Precision Medicines posts investor deck highlighting late-stage CNS pipeline, upcoming PDUFA dates
- PUBT · 1 day ago, 03:02 PM
Praxis Precision Medicines grants 7,318 RSUs to 29 new employees under 2024 inducement plan
- Unusual Whales · Jul 30 at 03:07 PM
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
- PUBT · Jul 30 at 03:01 PM
Praxis Precision Medicines to report Q2 results, host conference call and webcast
